FDA Approves First Oral PCSK9 Inhibitor Enlicitide
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- Enlicitide, sold by Merck as Lipfendra, was approved by the FDA last week to lower blood cholesterol — the first oral PCSK9 inhibitor on the market after years of injectable-only options.
- PCSK9 inhibitors, previously available only as injections, are powerful cholesterol-lowering medications whose development traces from families enrolled in the Dallas Heart Study through lab-bench discoveries to bedside care.
- New clinical guidelines backing a more aggressive approach to cholesterol reduction make enlicitide's arrival timely, particularly for the millions of Americans with established or high-risk cardiovascular disease.
- The STAT+ opinion piece, written by a cardiologist, acknowledges enlicitide 'has already been hailed as a game changer' but argues the question of whom it will actually help — and what it implies about prevention today — is 'more complicated' than the hype suggests.
- The full article is gated behind a STAT+ subscription, meaning the cardiologist's specific clinical objections are paywalled and only the framing skepticism is publicly visible.
Why it matters: An oral PCSK9 inhibitor removes the injection barrier that limited uptake among high-risk cardiovascular patients, but a practicing cardiologist is publicly pushing back on the 'game-changer' framing before the drug reaches the millions it is meant to serve — a tension between industry enthusiasm and bedside skepticism at the moment of FDA approval.
